ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines

Neuroendocrinology

Volumn 91, Issue 2, 2010, Pages 121-130

  Georgieva, I ^a   Koychev, D ^b   Wang, Y ^a   Holstein, J ^a   Hopfenmuller W ^c   Zeitz, M ^a   Grabowski, P ^a,d  

^a Gastroenterologie/Infektiologie/Rheumatologie   (Germany)

^b Medizinische Klinik III   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

Apoptosis; Aurora kinase inhibitor; Cell cycle; Gastroenteropancreatic neuroendocrine tumors; Prognostic markers; Proliferation; ZM447439

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; AURORA KINASE PROTEIN; CASPASE; CISPLATIN; CRYSTAL VIOLET; DOXORUBICIN; FLUOROURACIL; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; OCTREOTIDE; PROTEIN SERINE THREONINE KINASE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE PARAMETERS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOLOGY; DNA FRAGMENTATION; DRUG INHIBITION; ENZYME INHIBITION; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HUMAN CELL; IC 50; NEUROENDOCRINE TUMOR; PHASE TRANSITION; PRIORITY JOURNAL; TUMOR CELL;

EID: 77949906305     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000258705     Document Type: Article

References (42)

1. Arnold R: Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005; 19: 491-505.
2. Klöppel G: Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr Pathol 2007; 18: 141-144.
3. Kulke MH: Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am 2007; 21: 433-455.
4. Bolanos-Garcia VM: Aurora kinases. Int J Biochem Cell Biol 2005; 37: 1572-1577.
5. Tanaka E, Hashimoto Y, Ito T, Kondo K, Higashiyama M, Tsunoda S, Ortiz C, Sakai Y, Inazawa J, Shimada Y: The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin Cancer Res 2007; 13: 1331-1340.
6. Bischoff JR, Plowman GD: The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 1999; 9: 454-459.
7. Anand S, Penrhyn-Lowe S, Venkitaraman AR: Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3: 51-62.
8. Parra MT, Viera A, Gomez R, Page J, Carmena M, Earnshaw WC, Rufas JS, Suja JA: Dynamic relocalization of the chromosomal passenger complex proteins inner centromere protein (INCENP) and aurora-B kinase during male mouse meiosis. J Cell Sci 2003; 116: 961-974.
9. Grabowski P, Griss S, Arnold CN, Hörsch D, Göke R, Arnold R, Heine B, Stein H, Zeitz M, Scherübl H: Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Neuroendocrinology 2005; 81: 1-9.
10. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, Taguchi H, Yokoyama A: AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007; 110: 2034-2040.
11. Chieffi P, Cozzolino L, Kisslinger A, Libertini S, Staibano S, Mansueto G, De Rosa G, Villacci A, Vitale M, Linardopoulos S, Portella G, Tramontano D: Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 2006; 66: 326-333.
12. Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T, Ostrander EA, Stanford JL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman ED, Clayman GL, Lippman SM, Lee JJ, Zheng W, Balmain A: Aurora-A/ STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005; 26: 1368-1373.
13. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S: Overexpression of oncogenic STK15/BTAK/aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003; 9: 991-997.
14. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y: Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999; 59: 2041-2044.
15. Ulisse S, Delcros JG, Baldini E, Toller M, Curcio F, Giacomelli L, Prigent C, Ambesi- Impiombato FS, D'Armiento M, Arlot- Bonnemains Y: Expression of aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer 2006; 119: 275-282.
16. Mountzios G, Terpos E, Dimopoulos MA: Aurora kinases as targets for cancer therapy. Cancer Treat Rev 2008; 34: 175-182.
17. Andrews PD: Aurora kinases: shining lights on the therapeutic horizon? Oncogene 2005; 24: 5005-5015.
18. Carvajal RD, Tse A, Schwartz GK: Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006; 12: 6869-6875.
19. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ, Taylor SS: Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006; 119: 3664-3675.
20. Li X, Sakashita G, Matsuzaki H, Sugimoto K, Kimura K, Hanaoka F, Taniguchi H, Furukawa K, Urano T: Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C. J Biol Chem 2004; 279: 47201-47211.
21. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003; 161: 267-280.
22. Beardmore VA, Ahonen LJ, Gorbsky GJ, Kallio MJ: Survivin dynamics increases at centromeres during G2/M phase transition and is regulated by microtubule-attachment and Aurora B kinase activity. J Cell Sci 2004; 117: 4033-4042.
23. Walsby E, Walsh V, Pepper C, Burnett A, Mills K: Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008; 93: 662-669.
24. Long ZJ, Xu J, Yan M, Zhang JG, Guan Z, Xu DZ, Wang XR, Yao J, Zheng FM, Chu GL, Cao JX, Zeng YX, Liu Q: ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture. Cell Cycle 2008; 7: 1473-1479.
25. Evers BM, Ishizuka J, Townsend CM Jr, Thompson JC: The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann NY Acad Sci 1994; 733: 393-406.
26. Iguchi H, Hayashi I, Kono A: A somatostatin- secreting cell line established from a human pancreatic islet cell carcinoma (somatostatinoma): release experiment and immunohistochemical study. Cancer Res 1990; 50: 3691-3693.
27. Niles RM, Wilhelm SA, Steele GD Jr, Burke B, Christensen T, Dexter D, O'Brien MJ, Thomas P, Zamcheck N: Isolation and characterization of an undifferentiated human colon carcinoma cell line (MIP-101). Cancer Invest 1987; 5: 545-552.
28. Gillies RJ, Didier N, Denton M: Determination of cell number in monolayer cultures. Anal Biochem 1986; 159: 109-113.
29. Reiter R, Gais P, Jutting U, Steuer-Vogt MK, Pickhard A, Bink K, Rauser S, Lassmann S, Hofler H, Werner M, Walch A: Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 5136-5141.
30. Ikezoe T, Yang J, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, Taguchi H: A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 2007; 6: 1851-1857.
31. Kim KW, Mutter RW, Willey CD, Subhawong TK, Shinohara ET, Albert JM, Ling G, Cao C, Gi YJ, Lu B: Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys 2007; 67: 1519-1525.
32. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
33. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
34. Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G, Summerhayes IC: Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 1995; 11: 647-652.
35. Fogh J, Orfeo T, Tiso J, Sharkey FE: Establishment of human colon carcinoma lines in nude mice. Exp Cell Biol 1979; 47: 136-144.
36. Evers BM, Townsend CM Jr, Upp JR, Allen E, Hurlbut SC, Kim SW, Rajaraman S, Singh P, Reubi JC, Thompson JC: Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 1991; 101: 303-311.
37. Jumarie C, Malo C: Caco-2 cells cultured in serum-free medium as a model for the study of enterocytic differentiation in vitro. J Cell Physiol 1991; 149: 24-33.
38. Bjork P, Jonsson U, Svedberg H, Larsson K, Lind P, Dillner J, Hedlund G, Dohlsten M, Kalland T: Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J Biol Chem 1993; 268: 24232-24241.
39. Quinn LA, Moore GE, Morgan RT, Woods LK: Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res 1979; 39: 4914-4924.
40. Lundqvist M, Mark J, Funa K, Heldin NE, Morstyn G, Wedell B, Layton J, Oberg K: Characterisation of a cell line (LCC-18) from a cultured human neuroendocrine-differentiated colonic carcinoma. Eur J Cancer 1991; 27: 1663-1668.
41. Wolf B, Thompson J, Von Kleist S: Ultrastructural localization of carcino-embryonic antigen in a continuous human tumour cell line (LS 174 T) in relation to morphometric investigations. Anticancer Res 1984; 4: 213-219.
42. Park JG, Oie HK, Sugarbaker PH, Henslee JG, Chen TR, Johnson BE, Gazdar A: Characteristics of cell lines established from human colorectal carcinoma. Cancer Res 1987; 47: 6710-6718.